



PTO/SB/08a/b (06-03)

Approved for use through 07/31/2003 OMB 0651-0031
U S Patent and Trademark Office, U S DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	09/899,917-Conf. #528
				Filing Date	July 9, 2001
				First Named Inventor	Henrik S. Olsen
				Art Unit	1653
				Examiner Name	H. Robinson
Sheet	1	of	1	Attorney Docket Number	PF306D1

RECEIVED

OCT 06

2003

600/2900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-09/912,292	NOT PUBLISHED	ROSEN et al.	pages 1-75 (pages 1 & 2 partially redacted); portion of Table 2; and SEQ ID NO: 4971

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
					T ⁶

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------

Docket No.: PF306D1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Olsen et al.

Application No.: 09/899,917

Filed: July 9, 2001

Art Unit: 1653

For: Human Oncogene Induced Secreted Protein I

Examiner: H. Robinson

Supplemental Information Disclosure Statement Pursuant to 37 C.F.R. § 1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the reference AA listed on the attached revised Form PTO/SB/08.

Applicants wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding cDNA clone of the present application is related to SEQ ID NO:4971 in copending U.S. Application Serial No. 09/912,292. A legible copy of that portion of U.S. Patent Application Serial No. 09/912,292 which caused it to be listed on the attached form PTO/SB/08 is submitted herewith as reference AA. A copy of reference AA is enclosed.


Applicants respectfully request that the Examiner review the materials identified above and that they be made of record in the file history of the application.

Identification of the materials identified above is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that any such material is available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(c), this supplementary information disclosure statement, being filed after the mailing date of a first Office Action on the merits but before the mailing date of a final office action, a notice of allowance, or an action that otherwise closes prosecution in the application, is accompanied by the fee specified under 37 C.F.R. § 1.17(p). No further fee is believed due in connection with the filing of this paper. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Science, Inc., Deposit Account No. 08-3425.

Respectfully submitted,

Date: October 2, 2003


Lin J.Hymel (Reg. No. 45,414)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 251-6015 (telephone)

MMW/LJH/lcc
Enclosures